MOTS-c vs Retatrutide
Side-by-side comparison of key properties, dosing, and research.
Anti-Aging & Longevity
MOTS-cGLP-1 / Weight Loss Agonists
Retatrutide- Summary
- MOTS-c is a mitochondria-derived peptide (MDP) encoded within the mitochondrial genome. It acts as a metabolic regulator, improving insulin sensitivity, enhancing exercise capacity, and counteracting age-related metabolic decline. It is often called a 'mitochondrial hormone.'
- Retatrutide is an investigational triple receptor agonist targeting GLP-1, GIP, and glucagon receptors simultaneously. Phase 2 trials showed an unprecedented average 24% body weight reduction at 48 weeks — exceeding any approved medication to date. It is in Phase 3 trials as of 2024.
- Half-Life
- Estimated 1–2 hours
- ~10–12 days
- Admin Route
- SubQ
- SubQ
- Research
- —
- —
- Typical Dose
- 5–15 mg
- 0.5 mg → 1 mg → 2 mg → 4 mg → 8 mg → 12 mg
- Frequency
- 3–5 times per week
- Once weekly
- Key Benefits
- Improves insulin sensitivity and glucose metabolism
- Enhances exercise capacity and endurance
- Reduces age-related metabolic decline
- Activates AMPK — the master metabolic regulator
- Promotes fat oxidation
- Anti-inflammatory effects
- May extend healthspan via mitochondrial optimization
- Increases energy and reduces fatigue
- ~24% body weight reduction at 48 weeks in Phase 2 (highest dose)
- Superior to both semaglutide and tirzepatide in early trial comparisons
- Triple receptor mechanism addresses multiple obesity pathways
- Significant reduction in liver fat (MASH/NAFLD indication being studied)
- Improved cardiovascular and metabolic markers
- Once-weekly dosing
- Potential for greatest weight loss of any currently investigated compound
- Side Effects
- Injection site irritation
- Fatigue during initial adaptation
- Unknown long-term profile (limited human data)
- Nausea and vomiting (common during titration, similar to semaglutide/tirzepatide)
- Diarrhea
- Constipation
- Heart rate increase (from glucagon receptor agonism)
- +2 more
- Stacks With
- —
- —